Renal fibrosis is the histological manifestation of a progressive, usually irreversible process causing chronic and end-stage kidney disease. We performed genome-wide transcriptome studies of a large cohort (n = 95) of normal and fibrotic human kidney tubule samples followed by systems and network analyses and identified inflammation and metabolism as the top dysregulated pathways in the diseased kidneys. In particular, we found that humans and mouse models with tubulointerstitial fibrosis had lower expression of key enzymes and regulators of fatty acid oxidation (FAO) and higher intracellular lipid deposition compared to controls. In vitro experiments indicated that inhibition of FAO in tubule epithelial cells caused ATP depletion, cell death, dedifferentiation and intracellular lipid deposition, phenotypes observed in fibrosis. In contrast, restoring fatty acid metabolism by genetic or pharmacological methods protected mice from tubulointerstitial fibrosis. Our results raise the possibility that correcting the metabolic defect in FAO may be useful for preventing and treating chronic kidney disease. 
Although glomerular lesions are specific to the underlying etiology of a particular renal disease, fibrosis shows almost identical manifestation in all progressive forms of chronic kidney disease (CKD), suggesting it is a final common pathway in this condition 1, 2 . Fibrosis is characterized by a loss of capillary networks and an accumulation of fibrillary collagens, activated myofibroblasts and inflammatory cells 3, 4 . In renal fibrosis, tubular epithelial cells (TECs) are lost as a result of cell death, and the remaining cells dedifferentiate, leading to reduced expression of characteristic epithelial markers and increased expression of mesenchymal markers. Further, it has been found that increased tubular epithelial Notch, Wnt and Hedgehog signaling can induce dedifferentiation of TECs, a critical characteristic of CKD [5] [6] [7] . Although TECs may not be the direct precursors of myofibroblasts, they have an instrumental role in orchestrating renal fibrosis by multiple mechanisms, including secreting various cytokines. In particular, transforming growth factor-β 1 (TGFB1) is a key mediator of tissue fibrosis; it induces the secretion of fibrillary collagens and promotes cell death and dedifferentiation 8 .
Alteration in cellular metabolism, including changes in fuelsource preferences (glucose, fatty acids or ketones), has emerged as an important mechanism of cell differentiation, especially in the context of stem cells and carcinogenesis 9 . Metabolic reprogramming is a critical constituent of malignant transformation. Many cancers have increased glucose uptake and reduced mitochondrial glucose oxidation, a phenomenon called the Warburg effect. Very little is known about the metabolism of renal epithelial cells 10, 11 . Proximal TECs have high levels of baseline energy consumption and a copious supply of mitochondria. FAO is the preferred energy source for highly metabolic cells such as cardiac myocytes, as oxidation of fatty acids generates more ATP per molecule than does oxidation of glucose.
The uptake of long-chain fatty acids is facilitated by the longchain fatty acid transporter cluster of differentiation 36 (CD36) 12 . Metabolism of fatty acids requires their transport into the mitochondria, which is mediated by carnitine palmitoyltransferase 1 (CPT1), and this enzyme conjugates fatty acids with carnitine 13 . CPT1 is considered to be the rate-limiting enzyme in FAO. The peroxisome proliferator-activated receptors (PPARs) and PPAR-γ coactivator-1a (PPARGC1A) are the key transcription factors that regulate the expression of proteins involved in fatty acid uptake and oxidation [14] [15] [16] . Normally, fatty acid uptake, oxidation and synthesis are tightly balanced to avoid intracellular lipid accumulation.
Tubule epithelial lipid accumulation has received substantial attention, especially in the context of acute and diabetic kidney disease [17] [18] [19] [20] . It has been proposed that excess accumulation of triglycerides induces cellular lipotoxicity, potentially contributing to the development of renal fibrosis [17] [18] [19] [20] . For this reason, we took note when our unbiased gene profiling highlighted alterations in cellular metabolism in fibrotic kidneys. We uncovered that the levels of enzymes and regulators of FAO were reduced in kidneys from human subjects with CKD and in mouse models of kidney fibrosis. We found that healthy renal TECs rely primarily on FAO as their energy source. Lower FAO by TECs appears to contribute to the development of tubulointerstitial
RESULTS
The transcriptional landscape of human CKD samples To examine genome-wide transcript-level changes in samples from individuals with CKD, we collected and analyzed a large number (n = 95) of microdissected human kidney samples 21, 22 . As the patterns of diabetes-and hypertension-induced TIF are almost indistinguishable, we performed a combined analysis of tubulointerstitial samples obtained from individuals with diabetic or hypertensive CKD (Supplementary Table 1 ). We defined cases on the basis of their glomerular filtration rate (<60 cc/min/1.72 m 2 ) and by the presence of histological lesions of fibrosis. The analysis allowed us to identify common patterns and pathways that characterize CKD in human subjects. We identified 2,497 transcripts with a corrected P value of 0.05 and at least a 30% change in their expression values ( Supplementary Fig. 1 and Supplementary Table 2) .
Samples from individuals with diabetic and hypertensive CKD showed similar changes.
High-level pattern analysis using gene ontology tools highlighted the differential regulation of two key pathways: inflammation and metabolism. Inflammation is known to have an important functional role in the development of fibrosis (Fig. 1a) 23 . We also detected a very robust signal indicating the dysregulation of cellular metabolism in samples obtained from individuals with CKD ( Fig. 1a and  Supplementary Fig. 2 ). Gene ontology analysis highlighted specific changes in fatty acid metabolism, β-oxidation, amino acid catabolism and carbohydrate metabolism (Fig. 1a) . Gene set enrichment analysis confirmed the strong enrichment for FAO among the differently expressed pathways (Fig. 1b,c and Supplementary Fig. 2) . A more detailed interrogation indicated that the levels of genes related to fatty acid metabolism and their key transcriptional regulator complex, PPARA-PPARGC1A, were markedly lower in CKD samples compared to samples obtained from people with normal kidney function (controls) (Fig. 1d-f) . Levels of key regulators of glucose Relative mRNA (log) ACAT1  ALDH3A2  ACAA2  ADAA1  CYP4A11  ALDH7A1  ECHS1  ALDH1R1  ADHF  ALDH2  ADH5  ACOX1  HADH  ALDH9A1  ACADL  GCDH  CPT1A  CPT2  ACSL1  ACAT2  EHHADH  HADHA  ACADSR  ACSL5  ACSL4  ADH1R Control CKD npg utilization were lower in CKD samples compared to control samples (Fig. 1g) . The lower expression of key FAO regulators was associated with higher lipid accumulation in diseased renal TECs (Fig. 1e) . The mRNA levels of several mitochondrial enzymes and transcription factors were lower in CKD samples compared to controls, but we found no difference in mitochondrial DNA copy number ( Supplementary  Fig. 3a,b) . In summary, genome-wide unbiased transcript analysis of one of the largest collections of human kidney samples studied so far identified that the levels of enzymes and critical regulators of FAO are lower in kidneys with fibrosis compared to controls.
Genome-wide transcriptome analyses of mouse models of fibrosis Next we analyzed genome-wide transcriptional changes in mouse models of renal fibrosis 5 . We examined a genetic model of kidney fibrosis 5 created by transgenic overexpression of the Notch1 intracellular domain (ICNotch1) in TECs by using a doxycycline-inducible transgenic system (tetracycline-responsive element intracellular Notch1, or TRE-ICNotch1) (Supplementary Fig. 4a ). Breeding TRE-ICNotch1 mice with Pax8rtTA mice and placing them on a doxycycline-containing diet lead to tubule-specific expression of Notch1 and severe TIF (Fig. 2a ) 5 . We performed transcriptome analysis of kidneys from control (single-transgenic mice, TRE-ICNotch1 or Pax8rtTA, on doxycycline food) and Pax8rtTA/TRE-ICNotch1 mice using the Affymetrix ST1.0 platform 5 . Gene ontology analysis again indicated coordinated differences in metabolic pathways between the two groups (Fig. 2b) . We observed alterations in amino-acid, carbohydrate and fatty-acid metabolism in the Pax8rtTA/TRE-ICNotch mice compared to control mice. Transcript levels of key and ratelimiting enzymes of FAO (Cpt1 and Acox) and glucose utilization (Pgk and Pkm) were markedly lower in this mouse fibrosis model compared to controls (Fig. 2c,d ). Immunostaining studies confirmed lower expression of Ppara, a key regulator of lipid metabolism in Pax8rtTA/TRE-ICNotch1 mice, compared to controls (Fig. 2a) .
We observed similar changes in kidneys from mice with folic acidinduced kidney fibrosis (FAN mice). We found that protein and transcript levels of key FAO enzymes were lower in these mice (Fig. 2e) . Ppara and Ppargc1a mRNA levels were also lower (Fig. 2f,g ) and lipid accumulation (Fig. 2f) and triglyceride content (Fig. 2h) were higher in TECs from the FAN mice compared to sham-treated mice. Mitochondrial copy number was not changed in the FAN mice, but the expression of several mitochondrial specific genes was lower in kidneys from mice with FAN ( Supplementary Fig. 3c,d ). Timecourse experiments indicated that the lower expression of FAO in the FAN model preceded the expression of fibrosis markers Fig. 5a-c) , potentially suggesting a causal role. Thus, transcriptional changes of mouse models of kidney fibrosis show similar changes in metabolism-related transcript levels to samples obtained from individuals with CKD: lower levels of enzymes regulating fatty-acid and carbohydrate metabolism and high intracellular lipid accumulation.
Tubule epithelial lipid accumulation in CKD It has been proposed that increased lipid accumulation leads to lipotoxicity, contributing to fibrosis development 24 . Long-chain fatty acids, particularly palmitate and stearate, enter cells mostly through the long-chain fatty acid transporter CD36 (ref. 12) . To test the contribution of lipid accumulation (lipotoxicity) to fibrosis development, we generated a mouse model with kidney-specific overexpression of CD36. We created mice harboring human CD36 under a tetracyclineresponsive element (TRE) and crossed them with Pax8rtTA mice (Pax8rtTA/TRE-CD36 double-transgenic mice). Offsprings from this cross were induced to overexpress human CD36 specifically in TECs after administration of doxycycline at 4 weeks of age ( Fig. 3a and Supplementary Fig. 4b ). By 8 weeks of age, we observed considerable accumulation of intracellular lipids ( Fig. 3b ) and triglycerides in Pax8rtTA/TRE-CD36 animals compared to controls (Fig. 3c) . We performed fatty acid quantification by gas chromatography followed by flame ion diffusion (GC-FID), which indicated that the major fatty acid subtypes in the mouse kidney were stearic, palmitic, linoleic and docosahexaenoic acids ( Fig. 3d and Supplementary Table 3) . Levels of stearate and palmitate were markedly higher in the doubletransgenic animals compared to control (Pax8rtTA or TRE-CD36) animals (Supplementary Table 3 ). The concentration of shortchain fatty acids was slightly lower in kidney samples from doubletransgenic mice compared to samples from control mice. Quantitative analysis of markers of FAO indicated no change or only slightly higher expression of Cpt1a mRNA levels by 20 weeks of age in the doubletransgenic mice compared to controls (Fig. 3e) . Eight-week-old Pax8rtTA/TRE-CD36 mice (when fatty acid accumulation was already evident) showed little evidence of profibrotic marker expression (Fig. 3f) , Sirius Red staining (Fig. 3b) or changes in the levels of apoptosis-related genes (Fig. 3g) . By 20 weeks of age, we observed slightly higher expression of Acta2 and Col1a in these mice (Fig. 3f) . The double-transgenic animals did not show higher susceptibility to diabetic kidney injury induced by streptozotocin (Supplementary Fig. 6 ) or folic acid-induced fibrosis (data not shown). In summary, CD36 overexpression led to TEC lipid accumulation, but high lipid (triglyceride and long-chain fatty acid) levels alone were not sufficient to induce the full spectrum of fibrosis. We hypothesized that reduced fatty acid utilization (that is, FAO) could be the major inciting factor for fibrosis development and that lipid accumulation occurred as a secondary consequence. (Fig. 4a,b and Supplementary Fig. 7) . We found that OCR was markedly higher when we added palmitate to TECs and HKC-8 cells, indicating that TECs efficiently metabolize palmitate. The increase in OCR was sensitive to the CPT1 inhibitor etomoxir, confirming its specificity (Fig. 4a) . OCR was unchanged after glucose injection (Fig. 4b) ; however, ECAR was higher after glucose injection, indicating that glucose is used mainly for anaerobic glycolysis (lactate causes acidosis but does not consume oxygen) (Fig. 4b) . We found that FAO is the key contributor to intracellular ATP levels in TECs, as etomoxir treatment markedly reduced intracellular ATP content in these cells (Fig. 4c) . Etomoxir treatment was also associated with a higher apoptosis rate, i.e., more cells positive for cleaved caspase 3 and lower antiapoptotic BCL2 transcript levels (Fig. 4d,e) . Inhibition of FAO caused dedifferentiation of TECs, including the expression of ACTA2, VIM, COL1A1 and COL3A1 (Fig. 4f) , and more intracellular lipid droplet accumulation (Fig. 4d) . We observed similar results with ranolazine, a partial FAO inhibitor ( Supplementary  Fig. 8a-c) . In summary, we found that blockade of FAO was associated with higher levels of cell death, dedifferentiation and intracellular lipid accumulation, phenotypes that mimicked what we observed in human fibrotic kidneys.
TGFB1 suppresses FAO
TGFB1 is one of the most powerful profibrotic cytokines; therefore, we next examined the effect of TGFB1 on renal epithelial cell metabolism. As described previously 25 , treatment of HKC-8 cells and primary TECs with TGFB1 induced clear profibrotic phenotypic changes characterized by loss of an epithelial phenotype and acquisition of mesenchymal marker expression (COL1A1, COL3A1, VIM, FN and ACTA2) (Supplementary Fig. 8d,e) 25 . Cells treated with TGFB1 had lower baseline OCR and a reduction in palmitate-induced elevation in OCR, indicating low activity of fatty acid metabolism (Fig. 4g) . TGFB1 treatment reduced PPARA and PPARGC1A mRNA levels and those of their downstream targets CPT1 and ACOX (Fig. 4h) , which was probably the cause of the lower FAO. Consistent with the substantial metabolic depression, there was accumulation of Oil Red Opositive lipids (Fig. 4i) and lower cellular ATP content (Fig. 4j) in TGB1-treated cells. Levels of glucose metabolism-related enzymes (PFK1 and PK) (Supplementary Fig. 8f ) were lower in TGFB1-treated cells. Therefore, TGFB1 induces a metabolic reprogramming in TECs, specifically lowering FAO and increasing lipid accumulation.
Next we analyzed the molecular mechanism of TGFB1-induced FAO blockade. We found that the effects of TGFB1 were dependent on SMAD3. TGFB1 did not change the transcript levels of fatty acid metabolism-related enzymes (Cpt, Acox, Ppara and Ppargc1a) in Smad3-deficient primary mouse renal tubule cells ( Supplementary  Fig. 8g,h) . Furthermore, using publicly available chromatin immunoprecipitation and sequencing (ChIP-Seq) data, we identified that SMAD3 can bind directly to an intronic area on the PPARGC1A gene ( Fig. 5a) (GSE29422) 26 . This intronic area is outside the promoter region of PPARGC1A and does not overlap with active promoterspecific histone tail modifications (histone 3 Lys4 trimethylation (H3K4me3)) in human kidney TECs 27 . However, it does overlap with active enhancer-specific histone tail modifications (H3K4me1), and this region was a computationally annotated active enhancer in human kidney TECs, as determined by ChromHMM (Fig. 5a) 27 . PPARGC1A is a critical transcription factor that regulates mitochondrial biogenesis and the expression of almost all rate-limiting enzymes in the FAO pathway. We did not observe direct SMAD3 binding to PPARA. These results indicate that TGFB1, through SMAD3, can potentially regulate PPARGC1A transcript levels directly.
We next tested whether TGFB1-induced metabolic reprogramming was mediated by Ppargc1a using primary proximal TECs from mice with tubule-specific overexpression of Ppargc1a (Pax8rtTA/TRE-Ppargc1a mice). TECs from these mice showed no difference in palmitateinduced OCR after TGFB1 treatment (Fig. 5b) . Genetic overexpression of Ppargc1a normalized transcript levels of Cpt and other FAO-related enzymes (Fig. 5c) ; however, the defect in glucose utilization-related gene expression was not recovered in primary TECs obtained from Ppargc1a transgenic mice (Fig. 5d) . These results indicate that the TGFB1-induced FAO blockade is probably mediated by Ppargc1a.
Next we examined whether metabolic reprogramming has a role in development of the TGFB1-induced profibrotic phenotype. We found that TECs from Pax8rtTA/TRE-Ppargc1a mice were protected from TGFB1-induced functional changes, including the expression of profibrotic (Col3a1, Fn, Acta2 and Col4a1) and apoptosis-associated (Bcl2) genes (Fig. 5e,f) . These results indicate that metabolic gene expression changes have an important role in TGFB1-induced functional changes.
As Ppargc1a acts together with Ppara to regulate FAO, we examined the effect of the Ppara agonist fenofibrate. Fenofibrate normalized TGFB1-induced FAO repression (Fig. 5g) and the reductions in Cpt1 and Acox levels (Fig. 5h) but not the glucose-utilization defect (Fig. 5i) . Fenofibrate ameliorated TGFB1-induced dedifferentiation and apoptosis (Fig. 5j) . Thus, TGFB1-induced and Smad3-mediated repression of Ppargc1a and FAO are critical components of TGFB1-induced dedifferentiation and apoptosis in TECs.
Genetic or pharmacological improvement of FAO protects animals from kidney fibrosis
We next tested whether improving FAO in vivo in mouse models protects animals from the development of TIF. We used both transgenic and pharmacological approaches to investigate this issue. First we analyzed the effect of transgenic overexpression of Ppargc1a by intercrossing Pax8rtTA animals with TRE-Ppargc1a animals. We fed single-transgenic animals (both Pax8rtTA and TRE-Ppargc1a) and double-transgenic animals with food containing doxycycline starting at 4 weeks of age and induced TIF by folic acid administration at 6 weeks of age. Double-transgenic animals showed improvement in renal histology, as shown by periodic acid Schiff (PAS)-stained kidney sections and quantitative RT-PCR (qRT-PCR)-based quantification of profibrotic molecules (Fig. 6a,b) . Transgenic expression of Ppargc1a restored the expression of Cpt, which encodes the rate-limiting enzyme in FAO (Fig. 6c) . Transcript levels of enzymes involved in glucose metabolism showed no statistically significant changes between FA-treated controls and transgenic mice (Fig. 6e) . There was lower expression of apoptosis markers in tubules (cleaved caspase 3 staining and Bcl2 expression; Fig. 6a,d ) in the Pax8rtTA/ TRE-Ppargc1a transgenic animals. These results indicate that restoring enzyme levels related to FAO by transgenic overexpression of Ppargc1a, which did not impinge on glucose utilization, ameliorates fibrosis development.
Next we examined whether pharmacological activation of Ppara can also protect mice from the development of tubule epithelial fibrosis in the folic acid-induced injury model. We injected control and folate-injected mice with fenofibrate starting 1 day before folic acid injection. Fenofibrate administration strongly induced the transcript expression of the FAO-related genes Cpt1, Cpt2, Acox1 and Acox2 (Fig. 6f) . Folate-treated mice injected with fenofibrate had improved renal histology, lower expression of cleaved caspase 3 (Fig. 6g) , reduced fibrosis, kidney injury and apoptosis rate (Fig. 6h) and improved renal function (Fig. 6i) compared to sham-injected animals. However, enzyme levels related to glucose utilization were not recovered by fenofibrate treatment (Fig. 6j) . These observations were not limited to the folic acid-induced kidney fibrosis model, as we observed similar results analyzing the unilateral ureteral obstruction (UUO)-induced kidney fibrosis model. We found low expression of FAO-related genes in the UUO model (Supplementary Fig. 9 ). Treatment with fenofibrate restored FAO-related enzyme expression and resulted in lower expression of epithelial-injury (Kim-1, also called Havcr1) and fibrosis (collagens) markers (Supplementary Fig. 9 ).
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To provide additional evidence that kidney fibrosis is linked specifically to a defect in FAO, we tested the effect of etomoxir, a specific inhibitor of Cpt. Wild-type mice treated with etomoxir developed more severe kidney injury after folic acid injection and showed markedly higher expression of fibrosis markers and higher serum creatinine levels (Supplementary Fig. 10 ). Etomoxir inhibited Cpt and shifted metabolism to more glycolysis, as evident by higher Glut1 and Pfk1 expression. However, the glycolytic phenotype did not improve (and actually worsened) the development of fibrosis.
In addition, we also tested the effect of C75, a synthetic compound that increases Cpt1 activity and blocks fatty acid synthase 28 . C75 treatment of FAN mice restored the expression of Cpt1 and Acox1 and markedly lowered the apoptosis rate. C75 treatment improved kidney fibrosis and function in the folate-induced kidney fibrosis model ( Supplementary Fig. 11 ) without restoring the defect in glucose utilization, again indicating the critical role of FAO in fibrosis development.
DISCUSSION
In this study, we aimed to identify and examine common mechanisms of kidney fibrosis. Here we present genome-wide transcript data from a large cohort of kidney samples from individuals with CKD. Our unbiased studies indicated consistent differences in two gene groups: inflammation and metabolism. Several metabolic pathways were dysregulated in kidney fibrosis. Carbohydrate, amino-acid and lipid metabolism were markedly depressed in samples from patients with fibrosis.
Research into lipid metabolism in the kidney has been limited 29 . Clinical observations indicate a potential association between lipid levels and CKD development 30 . Most prior observations focused on higher lipid accumulation in TECs from kidneys of patients with CKD 12, 18 . Higher intracellular lipid accumulation has been proposed to have a key role in the development of fibrosis by inducing lipotoxicity 12, 20, 31 . However, our results indicate that higher intracellular triglyceride accumulation alone was not sufficient to induce the full spectrum of fibrosis in our CD36 transgenic mouse model and that substrate (fatty acid) uptake does not seem to be the limiting factor in kidney fibrosis. We also found that depressed FAO was associated with intracellular lipid accumulation (Supplementary Fig. 12 ). Our data therefore suggest a modest role for triglyceride accumulation per se in the development of kidney fibrosis. 
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We found that renal TECs depend critically on FAO as their energy source. This observation is in line with older studies showing that kidneys preferentially take up and oxidize fatty acids and are not a major contributor to circulating glucose catabolism 32 . As TECs are one of the cell types with the highest energy demands in the body, this carbon preference is quite logical. Other high energy-demanding organs (for example, the heart) also depend on FAO 24 .
Increased glucose utilization is the key metabolic phenotype of polycystic kidney disease and renal cell cancer 11, 33, 34 . It is important to note that in fibrosis, tubule cells did not markedly revert to glucose oxidation. Additional genetic mutations or signaling mechanisms are probably needed to make this metabolic switch, and simply losing the capacity for FAO does not induce a change in energy substrate preference. After inhibition of FAO in TECs, cellular ATP levels decreased, probably contributing to the increased apoptosis rate and dedifferentiation. The key observation of the current work is that decreased FAO alone was sufficient to reprogram TECs into a profibrotic phenotype, whereas improving FAO in mouse models of renal fibrosis restored TEC differentiation and reduced fibrotic injury.
We also found that TGFB1 appears to be an important upstream modulator of metabolism in renal TECs. In these cells, TGFB1 acted upstream of PPARGC1A. ChIP studies have indicated that Smad3 can bind directly to the Ppargc1a regulatory region 35 . A similar mechanism has already been described in adipocytes: a TGFB1-driven Smad3-dependent pathway appears to control Pgc1a and downstream fat deposition 35 . There might be other factors and cytokines that regulate Ppargc1a and FAO in kidney fibrosis ( Supplementary  Fig. 12) ; for example, Lkb1 and Ampk could be important controllers of FAO in TECs 36 (S.H.H. and K. Susztak, unpublished data). In our models and human samples, we did not observe a marked change in mitochondrial copy number; however, the expression of several important mitochondrial genes was lower in fibrotic kidney samples. As β-oxidation also takes places in the mitochondria, we cannot exclude that reduced FAO is just one manifestation of a broader mitochondrial dysfunction and/or oxidative phosphorylation defect. Mitochondrial dysfunction has been proposed to have an important role in the development of diabetic kidney disease 36 . Future studies will determine the role of FAO and mitochondria in fibrosis development. Performing metabolic studies in glomerular cells and glomerular injury models will also be important.
Our studies could have several important clinical implications. FAO inhibitors have received attention recently after it was found that these drugs sensitize leukemia cells for cell death, as leukemia cells use fatty acid as their key energy substrate 37 . Short-term treatment of animals with FAO inhibitors did not induce kidney fibrosis; however, mice treated with FAO inhibitors showed increased fibrosis after injury. Future studies will determine the long-term renal consequences of FAO inhibitors. Our experiments also indicate that drugs that enhance FAO might be of therapeutic benefit for patients with kidney fibrosis. For example, the Ppara agonist fenofibrate might confer therapeutic benefit for patients with CKD, as fenofibrate is widely used clinically for the treatment of hyperlipidemia. Indeed, long-term studies have indicated a reduction in albuminuria in patients with type 2 diabetes after fenofibrate treatment [38] [39] [40] . Unfortunately, the effect of fibrates on renal function is less obvious, as their use can be associated with a rise in serum creatinine levels. Our results indicate that agonists of Ppargc1 or Cpt1 might have a better therapeutic profile.
In summary, our studies show that decreased tubule epithelial FAO causes metabolic reprogramming of TECs, inducing increased apoptosis and dedifferentiation. Restoring FAO by genetic and pharmacological means protected mice from the development of fibrosis in several models. Thus, these insights could offer new therapeutic approaches for the treatment and prevention of kidney fibrosis in the clinic.
METhODS
Methods and any associated references are available in the online version of the paper. 
